Inhibition of TACE in human whole blood assessed as inhibition of LPS-stimulated TNFalpha production pretreated for 1 hr followed by LPS stimulation for 3.5 hrs by ELISA
AUC in rat assessed as (S)-5-(furo[3,2-b]pyridin-2-yl)-5-((6-methoxy-1-oxoisoindolin-2-yl)methyl)imidazolidine-2,4-dione level at 10 mg/kg, po by HPLC/MS analysis
AUC in rat assessed as (S)-5-(furo[3,2-b]pyridin-2-yl)-5-((6-methoxy-1-oxoisoindolin-2-yl)methyl)imidazolidine-2,4-dione level at 100 mg/kg, po administered as single dose by LC/MS/MS analysis
AUC in rat assessed as (S)-5-(furo[3,2-b]pyridin-2-yl)-5-((6-methoxy-1-oxoisoindolin-2-yl)methyl)imidazolidine-2,4-dione level at 300 mg/kg, po administered as single dose by LC/MS/MS analysis
AUC in rat assessed as (S)-5-(furo[3,2-b]pyridin-2-yl)-5-((6-methoxy-1-oxoisoindolin-2-yl)methyl)imidazolidine-2,4-dione level at 500 mg/kg, po administered as single dose by LC/MS/MS analysis
Oral bioavailability in rat assessed as (S)-5-(furo[3,2-b]pyridin-2-yl)-5-((6-methoxy-1-oxoisoindolin-2-yl)methyl)imidazolidine-2,4-dione level at 10 mg/kg by LC/MS/MS analysis
Oral bioavailability in monkey assessed as (S)-5-(furo[3,2-b]pyridin-2-yl)-5-((6-methoxy-1-oxoisoindolin-2-yl)methyl)imidazolidine-2,4-dione level by LC/MS/MS analysis
Oral bioavailability in dog assessed as (S)-5-(furo[3,2-b]pyridin-2-yl)-5-((6-methoxy-1-oxoisoindolin-2-yl)methyl)imidazolidine-2,4-dione level by LC/MS/MS analysis
Prodrug activation in human intestinal microsomes assessed as (S)-5-(furo[3,2-b]pyridin-2-yl)-5-((6-methoxy-1-oxoisoindolin-2-yl)methyl)imidazolidine-2,4-dione formation
Prodrug activation in mouse liver microsomes assessed as (S)-5-(furo[3,2-b]pyridin-2-yl)-5-((6-methoxy-1-oxoisoindolin-2-yl)methyl)imidazolidine-2,4-dione formation
Prodrug activation in rat liver microsomes assessed as (S)-5-(furo[3,2-b]pyridin-2-yl)-5-((6-methoxy-1-oxoisoindolin-2-yl)methyl)imidazolidine-2,4-dione formation
Prodrug activation in dog liver microsomes assessed as (S)-5-(furo[3,2-b]pyridin-2-yl)-5-((6-methoxy-1-oxoisoindolin-2-yl)methyl)imidazolidine-2,4-dione formation
Prodrug activation in monkey liver microsomes assessed as (S)-5-(furo[3,2-b]pyridin-2-yl)-5-((6-methoxy-1-oxoisoindolin-2-yl)methyl)imidazolidine-2,4-dione formation
Prodrug activation in human liver microsomes assessed as (S)-5-(furo[3,2-b]pyridin-2-yl)-5-((6-methoxy-1-oxoisoindolin-2-yl)methyl)imidazolidine-2,4-dione formation